Screener
Cogent Biosciences, Inc. COGT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Convertible senior notes, net | 223,173 | 222,895 |
| Operating lease liabilities, net of current portion | 14,097 | 14,355 |
| Other liabilities | 62 | 33 |
| Total liabilities | 295,313 | 301,236 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 8,979,420 shares authorized; no shares issued or outstanding | — | — |
| Series A non-voting convertible preferred stock, $0.001 par value; 1,000,000 shares authorized; 39,414 and 67,414 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 29,190 | 53,830 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s total liabilities?
- Cogent Biosciences, Inc. (COGT) reported total liabilities of $295.31M in Q1 2026.
- How has Cogent Biosciences, Inc.'s total liabilities changed year-over-year?
- Cogent Biosciences, Inc.'s total liabilities increased by 355.7% year-over-year, from $64.8M to $295.31M.
- What is the long-term trend for Cogent Biosciences, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s total liabilities has grown at a 79.3% compound annual growth rate (CAGR), from $16.25M to $301.24M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Cogent Biosciences, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude